This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| INVIVO | |
|---|---|
| Name | INVIVO |
| Type | Private |
| Industry | Medical devices; Biotechnology; Pharmaceuticals |
| Founded | 1990s |
| Headquarters | Luxembourg; Paris; Lyon |
| Area served | Global |
| Key people | CEO; CTO; Board |
| Products | Contrast agents; Imaging probes; Therapeutic agents; Diagnostic kits |
INVIVO
INVIVO is a multinational life sciences company specializing in contrast agents, molecular imaging probes, diagnostic reagents, and targeted therapeutics for preclinical and clinical use. It operates across Europe, North America, and Asia, supplying academic institutions, contract research organizations, biotechnology firms, and hospital systems. INVIVO maintains strategic relationships with universities, research institutes, pharmaceutical corporations, and health authorities to support translational science and regulatory approval pathways.
The company traces origins to collaborations among research groups at Université Paris-Sud, Université Lyon 1, and technology transfer offices associated with CNRS and Inserm in the 1990s. Early milestones included partnerships with Euratom-funded imaging projects and spin-outs linked to CEA laboratories and private investors from Luxembourg and the Île-de-France region. INVIVO expanded during the 2000s through licensing deals with biotechnology firms like Genzyme, distribution agreements with diagnostics companies such as PerkinElmer and Bruker Corporation, and manufacturing alliances with specialty chemical producers in the Bas-Rhin and Rhone-Alpes industrial zones. Subsequent growth involved acquisitions influenced by mergers in the pharmaceutical sector exemplified by Sanofi–Aventis consolidation trends and regulatory reforms following directives from the European Medicines Agency.
INVIVO offers a portfolio that includes gadolinium-based contrast agents used in magnetic resonance imaging, radiolabeled probes for positron emission tomography, fluorescent dyes for optical imaging, and nanoparticle formulations for targeted delivery. It supplies preclinical kits for pharmacokinetic assays favored by laboratories affiliated with Harvard University, Stanford University, University of Cambridge, University of Oxford, and Karolinska Institutet. Clinical product lines target diagnostic imaging suites in institutions such as Mayo Clinic, Cleveland Clinic, Guy's and St Thomas' NHS Foundation Trust, and Charité – Universitätsmedizin Berlin. Service offerings include custom synthesis, contract manufacturing for good manufacturing practice (GMP) clients, and analytical support often utilized by firms like Roche, Pfizer, AstraZeneca, and Novartis.
INVIVO's platform integrates chemistry and bioengineering advances similar to developments at MIT, ETH Zurich, and Johns Hopkins University. Core technologies encompass chelator design for radiometal binding, polymer conjugation methods inspired by work at Max Planck Institute for Polymer Research, and lipid nanoparticle encapsulation techniques paralleling innovations from Moderna collaborations. Proprietary processes focus on improving relaxivity of MRI agents, increasing specificity of receptor-targeted ligands for biomarkers like somatostatin receptors studied at Karolinska Institutet and M.D. Anderson Cancer Center, and optimizing radiochemistry modules compatible with cyclotron facilities such as those at Paul Scherrer Institute. INVIVO has adopted automation platforms influenced by companies like GE Healthcare and Siemens Healthineers to scale radiolabeling, and leverages analytical instrumentation from Agilent Technologies and Thermo Fisher Scientific.
Products are deployed in diagnostic pathways for oncology, neurology, cardiology, and infectious disease imaging. Clinical collaborators include oncology centers such as Institut Curie, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center for trials involving targeted PET tracers and MRI contrast agents to visualize tumor perfusion, receptor expression, and blood–brain barrier integrity. Neurology studies have partnered with University College London and Massachusetts General Hospital to examine demyelinating disease and neurodegeneration biomarkers. Cardiac imaging trials have linked INVIVO reagents with centers like Mount Sinai Hospital and Toronto General Hospital to assess myocardial viability and fibrosis. In infectious disease, tracer development echoes programs at Centers for Disease Control and Prevention and Institut Pasteur for pathogen-specific detection.
INVIVO operates as a privately held company with venture capital and strategic corporate investors from life science funds in Luxembourg, France, and Germany. Governance involves a board with representatives experienced at multinational corporations including Eli Lilly and Company, Bayer AG, and Johnson & Johnson. Operational divisions mirror industry practice at firms such as Stryker and Becton Dickinson with separate R&D, manufacturing, regulatory affairs, and commercial teams. Global distribution leverages logistics partners like DHL and cold-chain specialists used by UPS Healthcare to serve hospital networks and CROs including IQVIA and Labcorp.
INVIVO seeks approvals and conformity under frameworks administered by agencies such as the European Medicines Agency, U.S. Food and Drug Administration, and national competent authorities in countries including Germany, France, and Japan. Quality systems adhere to ISO 13485 standards and GMP guidance comparable to expectations for medical products at EMA-regulated firms. Safety monitoring aligns with pharmacovigilance practices observed at multinational pharmaceutical companies like GlaxoSmithKline and Bristol-Myers Squibb, and radiopharmaceutical operations comply with transport rules from the International Atomic Energy Agency and IATA regulations.
INVIVO engages in translational research consortia with academic centers such as Imperial College London, University of Toronto, Erasmus University Rotterdam, and University of California, San Francisco. Collaborative projects include multi-center clinical studies funded by European research programs and partnerships with biotechnology companies like Biogen and Amgen for companion diagnostic development. Preclinical collaborations extend to imaging core facilities at Wellcome Sanger Institute and cryo-electron microscopy groups at European Molecular Biology Laboratory to validate molecular targeting strategies. Industry alliances with contract research organizations and pharma incumbents support clinical trial implementation and technology licensing agreements.
Category:Medical imaging companies